<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>BioScreening.net &#187; Europe</title>
	<atom:link href="http://www.bioscreening.net/category/news-by-region/region-europe/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.bioscreening.net</link>
	<description>BioScreening news and events</description>
	<lastBuildDate>Thu, 29 Dec 2011 08:21:20 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3</generator>
		<item>
		<title>Positive agreement received for approval of AXANUM (low-dose ASA/esomeprazole) in Europe</title>
		<link>http://www.bioscreening.net/2011/08/02/positive-agreement-received-for-approval-of-axanum-low-dose-asaesomeprazole-in-europe/</link>
		<comments>http://www.bioscreening.net/2011/08/02/positive-agreement-received-for-approval-of-axanum-low-dose-asaesomeprazole-in-europe/#comments</comments>
		<pubDate>Tue, 02 Aug 2011 17:50:43 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[R & D]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1229</guid>
		<description><![CDATA[AstraZeneca today announced that AXANUM, a fixed dose combination of 81 mg low-dose ASA (acetylsalicylic acid) and 20 mg esomeprazole, has received positive agreement for approval in 23 European Union member countries and in Norway. AXANUM is indicated for prevention of cardiovascular (CV) events such as heart attack or stroke, in high-risk CV patients in [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/08/02/positive-agreement-received-for-approval-of-axanum-low-dose-asaesomeprazole-in-europe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Protein &#8216;helps predict Alzheimer&#8217;s risk&#8217;</title>
		<link>http://www.bioscreening.net/2011/06/23/protein-helps-predict-alzheimers-risk/</link>
		<comments>http://www.bioscreening.net/2011/06/23/protein-helps-predict-alzheimers-risk/#comments</comments>
		<pubDate>Thu, 23 Jun 2011 16:53:50 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Alzheimer's disease]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1170</guid>
		<description><![CDATA[A protein in spinal fluid could be used to predict the risk of developing Alzheimer&#8217;s disease, according to German researchers. Patients with high levels of the chemical &#8211; soluble amyloid precursor protein beta &#8211; were more likely to develop the disease, they found. Doctors said in the journal Neurology this was more precise than other [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/23/protein-helps-predict-alzheimers-risk/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Swine flu concerns in jails</title>
		<link>http://www.bioscreening.net/2011/05/20/swine-flu-concerns-in-jails/</link>
		<comments>http://www.bioscreening.net/2011/05/20/swine-flu-concerns-in-jails/#comments</comments>
		<pubDate>Fri, 20 May 2011 18:03:43 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Europe]]></category>
		<category><![CDATA[Swine Flu Research]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1112</guid>
		<description><![CDATA[In a confined space, a contagious illness like the swine flu (H1N1) could spread quickly.  It’s a problem health officials inside jails are thinking about as cases of swine flu fluctuate.  Many have come up with a health plan, but in Ireland their plan is raising eyebrows. In Ireland, swine flu cases are increasing rapidly which is forcing [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/05/20/swine-flu-concerns-in-jails/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Fragment Library</title>
		<link>http://www.bioscreening.net/2010/12/20/fragment-library/</link>
		<comments>http://www.bioscreening.net/2010/12/20/fragment-library/#comments</comments>
		<pubDate>Mon, 20 Dec 2010 18:59:24 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Compound Libraries]]></category>
		<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Diversity Libraries]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1069</guid>
		<description><![CDATA[Thermo Fisher Scientific Inc. announced that its Maybridge Ro3 Diversity Fragment Library has helped researchers validate an emerging technique for drug discovery that targets key protein receptors involved in a wide range of biological functions. David Myszka, founder of Biosensor Tools LLC and director of the Center for Biomolecular Interaction Analysis at the University of [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/12/20/fragment-library/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Could Starfish Inspire New Cure for Inflammation?</title>
		<link>http://www.bioscreening.net/2010/12/13/could-starfish-inspire-new-cure-for-inflammation/</link>
		<comments>http://www.bioscreening.net/2010/12/13/could-starfish-inspire-new-cure-for-inflammation/#comments</comments>
		<pubDate>Mon, 13 Dec 2010 21:25:06 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Antibiotics]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[New Drugs]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1053</guid>
		<description><![CDATA[Lurking in the seas of Scotland is an unlikely candidate for a medical breakthrough. But scientists believe the starfish could hold the key to finding a new treatment for inflammatory conditions such as asthma, hay fever and arthritis. The species they are interested in is the spiny starfish (Marthasterias glacialis), and in particular the slimy [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/12/13/could-starfish-inspire-new-cure-for-inflammation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biochromâ€™s new Anthos Instant Microplate Solution (AIMS)</title>
		<link>http://www.bioscreening.net/2009/11/11/biochrom%e2%80%99s-new-anthos-instant-microplate-solution-aims/</link>
		<comments>http://www.bioscreening.net/2009/11/11/biochrom%e2%80%99s-new-anthos-instant-microplate-solution-aims/#comments</comments>
		<pubDate>Wed, 11 Nov 2009 19:26:06 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Europe]]></category>
		<category><![CDATA[New Products]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/11/11/biochrom%e2%80%99s-new-anthos-instant-microplate-solution-aims/</guid>
		<description><![CDATA[If you have a new project a new job or a new lab you can stretch your budget further with Biochromâ€™s new Anthos Instant Microplate Solution (AIMS). This package has all the microplate instrumentation you need at a great price. AIMS is ideal for laboratories that handle a large number of ELISA or other absorbance [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/11/11/biochrom%e2%80%99s-new-anthos-instant-microplate-solution-aims/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Horizon Discovery signs screening agreement with SuperGen Inc.</title>
		<link>http://www.bioscreening.net/2009/08/21/horizon-discovery-signs-screening-agreement-with-supergen-inc/</link>
		<comments>http://www.bioscreening.net/2009/08/21/horizon-discovery-signs-screening-agreement-with-supergen-inc/#comments</comments>
		<pubDate>Fri, 21 Aug 2009 17:04:50 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Events]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/08/21/horizon-discovery-signs-screening-agreement-with-supergen-inc/</guid>
		<description><![CDATA[Horizon Discovery today announced it has signed a commercial agreement with US Pharmaceutical company SuperGen, Inc., relating to its X-MAN technology. Horizonâ€™s X-MAN (Mutant And Normal) cell-line technology provides the first genetically-defined and patient-relevant in vitro models of human cancer. These models are being used by a growing number of Pharma and Biotech companies to [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/08/21/horizon-discovery-signs-screening-agreement-with-supergen-inc/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>3rd International Symposium on Advances in Synthetic and Medicinal Chemistry</title>
		<link>http://www.bioscreening.net/2009/05/10/3rd-international-symposium-on-advances-in-synthetic-and-medicinal-chemistry/</link>
		<comments>http://www.bioscreening.net/2009/05/10/3rd-international-symposium-on-advances-in-synthetic-and-medicinal-chemistry/#comments</comments>
		<pubDate>Mon, 11 May 2009 02:19:35 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Compound Libraries]]></category>
		<category><![CDATA[Diversity Libraries]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Heterocyclic Chemistry]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/05/10/3rd-international-symposium-on-advances-in-synthetic-and-medicinal-chemistry/</guid>
		<description><![CDATA[Kiev, Ukraine, August 23 &#8211; 27, 2009 ASMC09 in Kiev is being prepared by EFMC (European Federation for Medicinal Chemistry) and ChemBridge Corporation, in the series of events which started with ASCMC04 Moscow followed by ASMC07 St. Petersburg. Prof. Erick Carreira, ETH Zurich, Switzerland and Dr Scott Biller, Novartis Institutes for BioMedical Research, Cambridge, USA, [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/05/10/3rd-international-symposium-on-advances-in-synthetic-and-medicinal-chemistry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Discovery and Selection &#8211; 45e RICT &#8211; Orleans, France, July 1-3, 2009</title>
		<link>http://www.bioscreening.net/2009/05/10/drug-discovery-and-selection-45e-rict-orleans-france-july-1-3-2009/</link>
		<comments>http://www.bioscreening.net/2009/05/10/drug-discovery-and-selection-45e-rict-orleans-france-july-1-3-2009/#comments</comments>
		<pubDate>Mon, 11 May 2009 01:34:35 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Europe]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/05/10/drug-discovery-and-selection-45e-rict-orleans-france-july-1-3-2009/</guid>
		<description><![CDATA[The upcoming edition of the RICT, the annual symposium of the SociÃ©tÃ© de Chimie ThÃ©rapeutique (SCT), will be held in OrlÃ©ans (France). This prestigious International Conference on Medicinal Chemistry will be organized by the University of OrlÃ©ans and the Institute of Organic and Analytical Chemistry (ICOA). Aim of the Symposium The major change which has [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/05/10/drug-discovery-and-selection-45e-rict-orleans-france-july-1-3-2009/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>KINAXOâ€™s Cellular Target ProfilingÂ® reveals mTOR as a new target of Celebrex</title>
		<link>http://www.bioscreening.net/2009/05/10/kinaxo%e2%80%99s-cellular-target-profiling%c2%ae-reveals-mtor-as-a-new-target-of-celebrex/</link>
		<comments>http://www.bioscreening.net/2009/05/10/kinaxo%e2%80%99s-cellular-target-profiling%c2%ae-reveals-mtor-as-a-new-target-of-celebrex/#comments</comments>
		<pubDate>Mon, 11 May 2009 00:46:24 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Proteomics]]></category>
		<category><![CDATA[Targeted Libraries]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/05/10/kinaxo%e2%80%99s-cellular-target-profiling%c2%ae-reveals-mtor-as-a-new-target-of-celebrex/</guid>
		<description><![CDATA[Martinsried, Germany, April 29, 2009 / b3c newswire /Â - Kinaxo Biotechnologies GmbH has successfully applied its Cellular Target ProfilingÂ® technology to identify the protein kinase mTOR as a new cellular target of celecoxib (CelebrexÂ®, Pfizer). Celecoxib is a non-steroidal, anti-inflammatory Cox-2 inhibitor approved for the treatment of osteoarthritis, rheumatoid arthritis and acute pain. In addition, [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/05/10/kinaxo%e2%80%99s-cellular-target-profiling%c2%ae-reveals-mtor-as-a-new-target-of-celebrex/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Salk Forms Stem Cell Partnership With Sanofi-Aventis</title>
		<link>http://www.bioscreening.net/2009/03/27/salk-forms-stem-cell-partnership-with-sanofi-aventis/</link>
		<comments>http://www.bioscreening.net/2009/03/27/salk-forms-stem-cell-partnership-with-sanofi-aventis/#comments</comments>
		<pubDate>Sat, 28 Mar 2009 01:35:53 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Collaborations]]></category>
		<category><![CDATA[Compound Libraries]]></category>
		<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/03/27/salk-forms-stem-cell-partnership-with-sanofi-aventis/</guid>
		<description><![CDATA[The Salk Institute says it has formed a new stem cell research partnership with Sanofi-Aventis, the international pharmaceutical giant based in Paris. Financial terms of the five-year alliance were not disclosed, and some details of the deal remain to be worked out, Salk spokesman Mauricio Minotta told me this afternoon. The Sanofi-Aventis regenerative medicine program [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/03/27/salk-forms-stem-cell-partnership-with-sanofi-aventis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Thermo Fisher Scientific Accelerates Drug Discovery Process With New Maybridge Quick2Leadâ„¢ Compound Kits</title>
		<link>http://www.bioscreening.net/2009/03/27/thermo-fisher-scientific-accelerates-drug-discovery-process-with-new-maybridge-quick2lead%e2%84%a2-compound-kits/</link>
		<comments>http://www.bioscreening.net/2009/03/27/thermo-fisher-scientific-accelerates-drug-discovery-process-with-new-maybridge-quick2lead%e2%84%a2-compound-kits/#comments</comments>
		<pubDate>Sat, 28 Mar 2009 01:32:03 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Compound Libraries]]></category>
		<category><![CDATA[Diversity Libraries]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/03/27/thermo-fisher-scientific-accelerates-drug-discovery-process-with-new-maybridge-quick2lead%e2%84%a2-compound-kits/</guid>
		<description><![CDATA[Thermo Fisher Scientific, the world leader in serving science, announced recently that it has introduced a novel tool to accelerate hit-to-lead programmes in the drug discovery process. Its Maybridge Quick2Leadâ„¢ Compound Kits are designed to save time and money by enabling rapid compound library synthesis around bioactive &#8220;hits&#8221; emerging from screening assays. The kits are [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/03/27/thermo-fisher-scientific-accelerates-drug-discovery-process-with-new-maybridge-quick2lead%e2%84%a2-compound-kits/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The French Institute I-Stem Realizes First Innovative Screens Using Stem Cells to Identify Drugs for Myotonic Dystrophy</title>
		<link>http://www.bioscreening.net/2009/03/20/the-french-institute-i-stem-realizes-first-innovative-screens-using-stem-cells-to-identify-drugs-for-myotonic-dystrophy/</link>
		<comments>http://www.bioscreening.net/2009/03/20/the-french-institute-i-stem-realizes-first-innovative-screens-using-stem-cells-to-identify-drugs-for-myotonic-dystrophy/#comments</comments>
		<pubDate>Fri, 20 Mar 2009 21:02:26 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Collaborations]]></category>
		<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[RNA Reasearch]]></category>
		<category><![CDATA[Stem Cell Research]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/03/20/the-french-institute-i-stem-realizes-first-innovative-screens-using-stem-cells-to-identify-drugs-for-myotonic-dystrophy/</guid>
		<description><![CDATA[EVRY, France, March 19 /PRNewswire/ &#8211;Â Â Â Â  Four research teams of I-STEM[*] have joined forces in a collaborative project that has just achieved a first pilot therapy-oriented screen of compounds and RNA interference aiming at reversing the altered phenotypes observed in human embryonic stem cells carrying the mutant gene for myotonic dystrophy type1. This assay inaugurates [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/03/20/the-french-institute-i-stem-realizes-first-innovative-screens-using-stem-cells-to-identify-drugs-for-myotonic-dystrophy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Flavor/Fragrance Ingredients in the Works</title>
		<link>http://www.bioscreening.net/2009/03/10/flavorfragrance-ingredients-in-the-works/</link>
		<comments>http://www.bioscreening.net/2009/03/10/flavorfragrance-ingredients-in-the-works/#comments</comments>
		<pubDate>Tue, 10 Mar 2009 04:21:57 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Europe]]></category>
		<category><![CDATA[Events]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Research Projects]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/03/10/flavorfragrance-ingredients-in-the-works/</guid>
		<description><![CDATA[DORTMUND, Germany and MILANâ€”The joint research efforts of InterMed Discovery (IMD) and Axxam SpA haveÂ resulted in a technology platform that offers screening solutions and the discovery of natural bioactive compounds valuable to companies in the food, beverages, flavor and fragrance industries. Based on that success, the companies signed a second joint research agreement that will [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/03/10/flavorfragrance-ingredients-in-the-works/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prous Institute Presents Innovative Approach to Drug Discovery</title>
		<link>http://www.bioscreening.net/2009/03/03/prous-institute-presents-innovative-approach-to-drug-discovery/</link>
		<comments>http://www.bioscreening.net/2009/03/03/prous-institute-presents-innovative-approach-to-drug-discovery/#comments</comments>
		<pubDate>Tue, 03 Mar 2009 07:44:41 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Events]]></category>
		<category><![CDATA[News by Region]]></category>
		<category><![CDATA[News by Subject]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/03/03/prous-institute-presents-innovative-approach-to-drug-discovery/</guid>
		<description><![CDATA[BARCELONA, February 26 /PRNewswire/ &#8212; Prous Institute for Biomedical Research today presented its strategies for drug discovery on its newly designed website (http://www.prousresearch.com). A large computational project with basic research support and broad disease coverage is being developed at Prous Institute under the broad-based Epistemic Drug Discovery(R) project. President and C.E.O. of the Institute, Dr. [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/03/03/prous-institute-presents-innovative-approach-to-drug-discovery/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>International Symposium Stem Cell Transplantation in Multiple Sclerosis: Sharing the Experience in Moscow, Russia on the 5th of October, 2009</title>
		<link>http://www.bioscreening.net/2009/01/23/international-symposium-stem-cell-transplantation-in-multiple-sclerosis-sharing-the-experience-in-moscow-russia-on-the-5th-of-october-2009/</link>
		<comments>http://www.bioscreening.net/2009/01/23/international-symposium-stem-cell-transplantation-in-multiple-sclerosis-sharing-the-experience-in-moscow-russia-on-the-5th-of-october-2009/#comments</comments>
		<pubDate>Sat, 24 Jan 2009 03:34:25 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Stem Cell Research]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/01/23/international-symposium-stem-cell-transplantation-in-multiple-sclerosis-sharing-the-experience-in-moscow-russia-on-the-5th-of-october-2009/</guid>
		<description><![CDATA[The Symposium is focused on the new modality of multiple sclerosis treatmentâ€“ immunosuppressive therapy followed by autologous stem cell transplantation. Centers in Europe, North and South America, Russia, China, Israel and Australia have successfully performed this procedure, and, to date, more than 600 stem cell transplantations in multiple sclerosis have been performed worldwide. Along with [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/01/23/international-symposium-stem-cell-transplantation-in-multiple-sclerosis-sharing-the-experience-in-moscow-russia-on-the-5th-of-october-2009/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nanion nominated for The German Industryâ€™s Innovation Award</title>
		<link>http://www.bioscreening.net/2009/01/23/nanion-nominated-for-the-german-industry%e2%80%99s-innovation-award/</link>
		<comments>http://www.bioscreening.net/2009/01/23/nanion-nominated-for-the-german-industry%e2%80%99s-innovation-award/#comments</comments>
		<pubDate>Sat, 24 Jan 2009 02:22:53 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Equipment & Supplies]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Grants and Awards]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/01/23/nanion-nominated-for-the-german-industry%e2%80%99s-innovation-award/</guid>
		<description><![CDATA[Munich, Germany, Jan 20th, 2009; Nanion is again nominated for a prestigious innovation award, due its impressive product portfolio of automated patch clamp systems. More than 350 companies competed in this yearâ€™s Innovation Award and Nanion is finalist in the category â€œStart-Up Companiesâ€. The German Industryâ€™s Innovation Award, also the worldâ€™s first innovation award, has [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/01/23/nanion-nominated-for-the-german-industry%e2%80%99s-innovation-award/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease</title>
		<link>http://www.bioscreening.net/2009/01/23/richter-helm-and-athera-biotechnologies-partner-in-development-of-recombinant-protein-to-treat-cardiovascular-disease/</link>
		<comments>http://www.bioscreening.net/2009/01/23/richter-helm-and-athera-biotechnologies-partner-in-development-of-recombinant-protein-to-treat-cardiovascular-disease/#comments</comments>
		<pubDate>Sat, 24 Jan 2009 02:19:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Collaborations]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/01/23/richter-helm-and-athera-biotechnologies-partner-in-development-of-recombinant-protein-to-treat-cardiovascular-disease/</guid>
		<description><![CDATA[Hamburg, Germany and Stockholm, Sweden, January 21st, 2009 &#8212; Richter-Helm BioLogics GmbH &#038; Co. KG and Athera Biotechnologies AB have signed an agreement for the development and manufacturing of Atheraâ€™s novel product for prevention of plaque rupture and athero-thrombosis through binding of the protein, Annexin A5, to endothelium. The recombinant protein Annexin A5 is intended [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/01/23/richter-helm-and-athera-biotechnologies-partner-in-development-of-recombinant-protein-to-treat-cardiovascular-disease/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>International symposium &#8220;Stem Cell Transplantation in Multiple Sclerosis, October 5th, 2009 Moscow, Russia</title>
		<link>http://www.bioscreening.net/2009/01/13/international-symposium-stem-cell-transplantation-in-multiple-sclerosis-october-5th-2009-moscow-russia/</link>
		<comments>http://www.bioscreening.net/2009/01/13/international-symposium-stem-cell-transplantation-in-multiple-sclerosis-october-5th-2009-moscow-russia/#comments</comments>
		<pubDate>Tue, 13 Jan 2009 22:19:18 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/01/13/international-symposium-stem-cell-transplantation-in-multiple-sclerosis-october-5th-2009-moscow-russia/</guid>
		<description><![CDATA[International symposium &#8220;Stem Cell Transplantation in Multiple Sclerosis: Sharing the Experience&#8221; will be heldÂ  on October 5th, 2009 inÂ  Moscow, Russia. Symposuim Organizers are Pirogov National Medical Surgical Center, National Center for Research and Treatment of Autoimmune Diseases, Russian Cooperative Group for Cellular Therapy, New Jersey Center for Quality of Life and Health Outcomes Research. [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/01/13/international-symposium-stem-cell-transplantation-in-multiple-sclerosis-october-5th-2009-moscow-russia/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Galapagos enters strategic alliance in diabetes and obesity with Merck &amp; Co., Inc.</title>
		<link>http://www.bioscreening.net/2009/01/12/galapagos-enters-strategic-alliance-in-diabetes-and-obesity-with-merck-co-inc/</link>
		<comments>http://www.bioscreening.net/2009/01/12/galapagos-enters-strategic-alliance-in-diabetes-and-obesity-with-merck-co-inc/#comments</comments>
		<pubDate>Mon, 12 Jan 2009 19:47:55 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Collaborations]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Targeted Libraries]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/01/12/galapagos-enters-strategic-alliance-in-diabetes-and-obesity-with-merck-co-inc/</guid>
		<description><![CDATA[Galapagos NV (Euronext: GLPG) announced today that it has entered into a multi-year global strategic alliance with Merck &#038; Co., Inc. to develop potential new therapies in obesity and diabetes. Galapagos will be responsible for the discovery and pre-clinical development of new small molecule candidate drugs based on novel Galapagos targets. Merck will have the [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/01/12/galapagos-enters-strategic-alliance-in-diabetes-and-obesity-with-merck-co-inc/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

